Characteristic | N/total # pts (%) |
---|---|
Response on prior anti-EGFR therapy | |
  Response or stable disease ≥6 m | 37/89 (42) |
  No response or stable disease <6 m | 52/89 (58) |
Clinical benefit on anti-EGFR retreatment | Â |
  Best response CR/PR/SD | 50/86 (58) |
  Best response PD | 36/86 (42) |
Prior anti-EGFR-based regimens | Â |
  Panitumumab monotherapy | 6/89 (7) |
  Panitumumab + Chemotherapya | 9/89 (10) |
  Panitumumab and AMG-102/AMG-479 | 1/89 (1) |
  Cetuximab monotherapy | 2/89 (2) |
  Cetuximab + Chemotherapyb | 71/89 (80) |
Anti-EGFR-based retreatment regimens | Â |
  Cetuximab, FOLFOX, and dasatinib | 31/89 (35) |
  Cetuximab, irinotecan, and bevacizumab | 12/89 (13) |
  Cetuximab and erlotinib | 13/89 (15) |
  Cetuximab and sirolimus | 11/89 (12) |
  Cetuximab, HAIc oxaliplatin, 5-FU, bevacizumab | 20/89 (23) |
  Cetuximab, HAI oxaliplatin, and bevacizumab | 2/89 (2) |
Interval length between prior and retreatment anti-EGFR therapies | Months |
  Median | 4.57 |
  Mean ± Standard Deviation | 7.34 ± 8.9 |
  Range | 0.46 – 58.7 |